<DOC>
	<DOCNO>NCT02056938</DOCNO>
	<brief_summary>The primary objective follow randomize open label trial demonstrate low immunological risk patient ( anti HLA immunization first kidney transplantation ) diagnose high-risk delayed graft function ( assessed DGFS score ) could benefit induction ATG prevent delay graft function compare Basiliximab .</brief_summary>
	<brief_title>ATG Versus Basiliximab Kidney Transplant Displaying Low Immunological Risk But High Susceptibility DGF</brief_title>
	<detailed_description />
	<mesh_term>Disease Susceptibility</mesh_term>
	<mesh_term>Delayed Graft Function</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adults First kidney transplantation No anti HLA immunization prior transplantation A risk DGF high 40 % calculate score DGFS ( DGFS &gt; = 0.4 ) Written inform consent Previous combine transplantation Non heart beat donor Living donor Preemptive transplantation Patients peritoneal dialysis Leucopenia low 3000/mm3 Thrombopenia low 100 000/mm3 Donor EBV positive / recipient EBV Negative Pregnant lactate woman Patients guardianship Previous current history cancer and/or lymphoma Current history HCV HBV HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Transplantation</keyword>
	<keyword>kidney</keyword>
	<keyword>delay graft function</keyword>
	<keyword>induction therapy</keyword>
	<keyword>personalize medicine</keyword>
	<keyword>First kidney transplantation</keyword>
	<keyword>No anti HLA immunization prior transplantation</keyword>
	<keyword>Risk DGF high 40 % calculate byt score DGFS</keyword>
</DOC>